Truist analyst David MacDonald lowered the firm’s price target on Tenet Healthcare (THC) to $175 from $190 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 for Healthcare Services. The firm sees the outlook for the group as “mixed”, with bullish stance on the underlying demand drivers and overarching sector tailwinds that include demographics, value-based care, and core demand being offset by heightened concern around a likely more cost focused government backdrop. Selectivity is key and cash flow generation with broadly attractive financial flexibility are set to provide solid support, while the recent valuation re-rating for several names provides a better setup around risk/reward, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare assumed with an Overweight at JPMorgan
- Netflix, MongoDB downgraded: Wall Street’s top analyst calls
- Tenet Healthcare downgraded to Neutral from Buy at Goldman Sachs
- Block, Five Below downgraded: Wall Street’s top analyst calls
- Tenet Healthcare downgraded to Equal Weight from Overweight at Wells Fargo